Disc Medicine (IRON) Price & Analysis

Compare

530 Followers

IRON Stock Chart & Stats

$87.49

$0.74(1.19%)

At close: Jan 08 4:00 PM EST

$87.49

$0.74(1.19%)

Day’s Range― - ―

52-Week Range$30.82 - $99.50

Previous CloseN/A

Volume41.94K

Average Volume (3M)510.11K

Market Cap

$3.45B

Enterprise Value$1.74B

Total Cash (Recent Filing)$615.92M

Total Debt (Recent Filing)$30.98M

Price to Earnings (P/E)―

Beta1.71

Next Earnings

Mar 27, 2026

EPS Estimate

-1.75

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.77

Shares Outstanding37,750,160

10 Day Avg. Volume470,680

30 Day Avg. Volume510,108

Financial Highlights & Ratios

PEG Ratio-1.01

Price to Book (P/B)3.95

Price to Sales (P/S)0.00

P/FCF Ratio-18.53

Enterprise Value/Market Cap0.50

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-18.12K

Enterprise Value/Ebitda-10.76

Forecast

1Y Price Target

$120.18

Price Target Upside37.36% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-6.15

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug Development And Clinical TrialsDISC-0974 showed positive clinical effects on anemia across a broad range of patients in the RALLY-MF study.

Financial Position And Market PotentialDisc Medicine has a strong financial position, ending the period with $615.9M in cash, cash equivalents, and investments, and extending its cash runway into 2029 after a public offering.

Regulatory Approval And Market LaunchThe NDA was submitted and the FDA delivered a significant vote of confidence by awarding a CNPV, which could support accelerated approval.

Bears Say

Disc Medicine News

3 ‘Strong Buy’ Stocks to Buy Today, 12/8/2025, According to Top Analysts

Looking for top-rated stocks to buy now? Recent analyst updates highlight three companies that have earned Strong Buy...

11d ago

BCAX

HASI

Disc Medicine presents initial data from RALLY-MF Phase 2 trial of DISC-0974

Disc Medicin presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF...

12d ago

IRON

Disc Medicine’s Promising Position in Anemia Treatment Boosts Buy Rating Amidst Competitor Setback

Disc Medicine, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from...

10d ago

IRON

Disc Medicine Advances Bitopertin in FDA Pilot Program

Disc Medicine ( ($IRON) ) has shared an announcement. On December 7, 2025, Disc Medicine held a conference...

11d ago

IRON

Evan Seigerman Recommends Buy Rating for Disc Medicine Due to Promising Phase 2 Data and Potential Stock Appreciation

BMO Capital analyst Evan Seigerman has maintained their bullish stance on IRON stock, giving a Buy rating today....

11d ago

IRON

Disc Medicine’s Promising Pipeline and Strategic Expansion Drive Buy Rating

Analyst Sean Laaman from Morgan Stanley maintained a Buy rating on Disc Medicine and keeping the price target...

11d ago

IRON

Disc Medicine’s Growth Potential Driven by Innovative Treatments and Promising Market Opportunities

TD Cowen analyst Tara Bancroft has maintained their bullish stance on IRON stock, giving a Buy rating on...

1M ago

IRON

Disc Medicine price target raised to $114 from $86 at Truist

Truist raised the firm’s price target on Disc Medicine (IRON) to $114 from $86 and keeps a Buy...

1M ago

IRON

Disc Medicine: Strong Financial Position and Promising Product Pipeline with Bitopertin’s Billion-Dollar Potential

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Disc Medicine. The associated price target...

1M ago

IRON

Disc Medicine Advances Pipeline Amid Financial Growth

Disc Medicine, Inc. ( ($IRON) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

IRON

Disc Medicine’s Promising Pipeline and Regulatory Advancements Justify Buy Rating

TD Cowen analyst Tara Bancroft has maintained their bullish stance on IRON stock, giving a Buy rating on...

1M ago

IRON

Disc Medicine reports Q3 EPS ($1.77), consensus ($1.47)

“We are incredibly proud of the progress across our entire pipeline this quarter, most notably around our NDA...

1M ago

IRON

Disc Medicine resumed with a Buy at Stifel

Stifel analyst Stephen Willey resumed coverage of Disc Medicine (IRON) with a Buy rating and $125 price target...

2M ago

IRON

Disc Medicine’s APOLLO Study: A Potential Game-Changer for EPP and XLP Treatment

Disc Medicine, Inc. (($IRON)) announced an update on their ongoing clinical study. Disc Medicine, Inc. is conducting a...

2M ago

IRON

IRON FAQ

What was Disc Medicine’s price range in the past 12 months?

Disc Medicine lowest stock price was $30.82 and its highest was $99.50 in the past 12 months.

What is Disc Medicine’s market cap?

Disc Medicine’s market cap is $3.45B.

When is Disc Medicine’s upcoming earnings report date?

Disc Medicine’s upcoming earnings report date is Mar 27, 2026 which is in 98 days.

How were Disc Medicine’s earnings last quarter?

Disc Medicine released its earnings results on Nov 06, 2025. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$1.442 by -$0.328.

Is Disc Medicine overvalued?

According to Wall Street analysts Disc Medicine’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Disc Medicine pay dividends?

Disc Medicine does not currently pay dividends.

What is Disc Medicine’s EPS estimate?

Disc Medicine’s EPS estimate is -1.75.

How many shares outstanding does Disc Medicine have?

Disc Medicine has 37,750,160 shares outstanding.

What happened to Disc Medicine’s price movement after its last earnings report?

Disc Medicine reported an EPS of -$1.77 in its last earnings report, missing expectations of -$1.442. Following the earnings report the stock price went down -1.483%.

Which hedge fund is a major shareholder of Disc Medicine?

Currently, no hedge funds are holding shares in IRON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Disc Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

-34.78%

Trailing 12-Months

Asset Growth

27.33%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Disc Medicine

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Disc Medicine (IRON) Earnings & Revenues

Historic Earnings Reports

IRON Stock 12 Month Forecast

Average Price Target

$120.18

▲(37.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","155":"$155","73.25":"$73.3","100.5":"$100.5","127.75":"$127.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":154,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$154.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$120.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,73.25,100.5,127.75,155],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.69,96.48307692307692,101.27615384615385,106.06923076923077,110.8623076923077,115.65538461538462,120.44846153846154,125.24153846153845,130.0346153846154,134.8276923076923,139.62076923076924,144.41384615384615,149.2069230769231,{"y":154,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.69,93.88153846153845,96.07307692307693,98.26461538461538,100.45615384615385,102.64769230769231,104.83923076923077,107.03076923076924,109.2223076923077,111.41384615384615,113.60538461538462,115.79692307692308,117.98846153846154,{"y":120.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.69,92.32923076923076,92.96846153846154,93.6076923076923,94.24692307692308,94.88615384615385,95.52538461538461,96.16461538461539,96.80384615384615,97.44307692307692,98.0823076923077,98.72153846153846,99.36076923076924,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":64.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.69,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >